OneAscent Family Office, LLC reported NORTHERN LTS FD TR IV (IBD) in 6 quarterly 13F filings from 2024 Q4 through 2026 Q1. Peak portfolio weight reached 1.51% in 2024 Q4. The latest visible filing shows IBD at 0.58% of the fund.
This page tracks quarterly shares, estimated market value, portfolio weight, filing dates, and disclosure-aligned stock prices directly from SEC EDGAR 13F filings.
This page is designed to answer the real investor question behind a 13F filing: how meaningful was OneAscent Family Office, LLC's position in NORTHERN LTS FD TR IV, and how did that conviction change over time? You can read the holding window, peak weight, latest reported size, disclosure timing, and quarter-by-quarter changes without piecing the story together from raw SEC rows.
IBD was reported at 0.58% of portfolio in the most recent visible filing.
Peak weight helps separate a token disclosure from a real conviction holding the fund genuinely cared about.
Longer holding windows often tell a very different story from short-lived tactical trades or one-quarter experiments.
Knowing that a fund owned a stock is useful. Knowing whether it was a 0.20% placeholder or a true high-conviction position is where the signal actually starts.
These are the practical questions this page is built to answer before you even open the full history table.
OneAscent Family Office, LLC reported IBD across 6 quarterly 13F filings, from 2024 Q4 through 2026 Q1.
The largest reported portfolio weight for IBD was 1.51% in 2024 Q4.
The most recent filing on this page is 2026 Q1, when OneAscent Family Office, LLC reported 35,073 shares, equal to 0.58% of portfolio, with an estimated market value of $837K.
The chart compares OneAscent Family Office, LLC's quarterly IBD portfolio weight with the stock's indexed share price, so you can see whether the fund was building, trimming, or holding the position as price moved.
Based on 13F filing dates vs. subsequent IBD price moves, OneAscent Family Office, LLC correctly timed 1 out of 5 reported position changes (20%). The annualised alpha on IBD relative to SPY over the holding period was -8.1%.